ClinicalTrials.gg
RecruitingNCT06908356Updated Apr 3, 2025

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

A Phase 2 interventional study of 30mg PRAX-628 in Focal Onset Seizure and Primary Generalized Epilepsy, sponsored by Praxis Precision Medicines. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Praxis Precision Medicines · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Planned enrollment
159th of 306
50 · median 56
Started
2025
with 19 others
Phase 2
64 of 395
10 open now
Primary completion
2025-07
later than 3 of 91 live
Registered
366th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 159th largest by planned enrollment of the 306 interventional ones that give a count, is one of 20 that started in 2025, is one of 64 in phase 2, reaches primary completion later than 3 of the 91 other live ones, and was the 366th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures

Read the detailed description

An open label clinical trial to evaluate the efficacy and safety of PRAX-628 in adult patients with focal onset or primary generalized tonic-clonic seizures who can attest to concurrently taking at least 1, but no more than 3 acceptable anti-seizure medications.

03

Conditions studied

  • Focal Onset Seizure
  • Primary Generalized Epilepsy

Keywords

  • Focal Onset Seizure
  • Primary Generalized Epilepsy
  • Tonic-Clonic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of focal onset seizures or idiopathic generalized tonic clonic seizures.
  • Evidence by computed tomography (CT) or magnetic resonance imaging (MRI) in the past that has ruled out a progressive cause of epilepsy.
  • Participant must have been receiving stable doses of allowable ASMs (a minimum of 1 and a maximum of 3 ASMs).
  • Participant and/or caregiver (if applicable) self-reports at least 2 countable focal onset seizures per month for focal onset patients, or 1 countable generalized tonic-clonic seizure per month in the 3 months immediately prior to the Screening/Observation Period for PGTCS patients.

Exclusion criteria

Exclusion Criteria:

  • History of pseudo or psychogenic seizures, or cluster seizures only, within the 12-month period preceding study entry where the individual seizures cannot be counted, or an episode of convulsive status epilepticus requiring hospitalization and intubation in the 12 months prior to Screening.
  • Planned epilepsy surgery during the course of the clinical trial.
  • History of neurosurgery for seizures \<1 year prior to enrollment, or radiosurgery \<2 years prior to enrollment.
  • Schizophrenia and obsessive-compulsive disorder, or other serious mental health disorders.
  • Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt.
  • Participants with a history of , myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.
  • History of cardiac disease(s)/cardiac conduction disorders/or cardiac structural abnormality(ies).
  • Is pregnant or breastfeeding at the time of Screening, or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose.
  • Has received any other experimental or drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene therapy.
  • Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.
  • Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Open-label 30mg/day PRAX-628 for 8 weeks

    Participants who meet all eligibility criteria will receive 30mg of PRAX-628 for 8 weeks.

    Drug: 30mg PRAX-628

Interventions

  • Drug30mg PRAX-628

    Once daily oral

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of PRAX-628 on seizure frequency in adults with FOS or PGTCS currently taking ASMs

    Median percent change in monthly (28 days) seizure frequency from the Screening/Observation Period to the Treatment Period for PRAX-628

    Time frame: 8 weeks

Secondary outcomes

  1. To evaluate the efficacy of PRAX 628 on seizure frequency in adults with FOS or PGTCS currently taking ASMs

    • Proportion of participants experiencing a ≥50% reduction in monthly (28 days) seizure frequency from the Screening/Observation Period to the Treatment Period (Responder Rate) for PRAX-628.

    Time frame: 8 weeks

  2. To evaluate the efficacy of PRAX 628 on seizure frequency in adults with FOS or PGTCS currently taking ASMs

    • Proportion of participants experiencing seizure freedom, 100% reduction in monthly (28 days) seizure frequency from the Screening/Observation Period to the Treatment Period for PRAX-628.

    Time frame: 8 weeks

  3. To evaluate the efficacy of PRAX 628 on seizure frequency in adults with FOS or PGTCS currently taking ASMs

    • Number of days after the first administration of PRAX-628 to reach the same or higher number of monthly seizures from the Screening/Observation Period to the Treatment Period

    Time frame: 8 weeks

  4. CGI-S Change from Baseline

    CGI-S assesses the clinician's impression of the participant's current illness state. The clinician should use his/her total clinical experience with this patient population and rate the current severity on a 7-point scale from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: 8 weeks

  5. PGI-S Change from Baseline

    PGI-S assesses the participants' impression of their current illness state. The participant is required to assess their condition on a 7-point scale from 1 (Not present) to 7 (extremely severe).

    Time frame: 8 weeks

  6. To assess the safety and tolerability of PRAX-628 in adults with FOS or PGTCS currently taking ASMs

    The number of participants with Adverse Events (AE) will be reported by preferred term

    Time frame: 8 weeks

07

Study locations

11 of 11 sites recruiting
  • Praxis Research Site
    Phoenix, Arizona 85032, United States
    Recruiting
  • Praxis Research Site
    Miami Lakes, Florida 30116, United States
    Recruiting
  • Praxis Research Site
    Bethesda, Maryland 20817, United States
    Recruiting
  • Praxis Research Site
    Chesterfield, Missouri 63005, United States
    Recruiting
  • Praxis Research Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Praxis Research Site
    Middletown, New York 10941, United States
    Recruiting
  • Praxis Research Site
    Round Rock, Texas 78681, United States
    Recruiting
  • Praxis Research Site
    Seabrook, Texas 77586, United States
    Recruiting
  • Praxis Research Site
    Heidelberg, 03084, Australia
    Recruiting
  • Praxis Research Site
    Melbourne, 03004, Australia
    Recruiting
  • Praxis Research Site
    Madrid, 28010, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2025, 6 months after the start.

Of 35 phase 2 interventional studies under Seizures, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Apr 3, 2025
StartActual
Jan 10, 2025
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06908356
Lead sponsor
Praxis Precision Medicines
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Jan 10, 2025
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Apr 3, 2025

Study contacts

Head of Pharmacovigilance
Contact
clinicaltrials@praxismedicines.com
617-300-8460
Medical Director
study director · Praxis Precision Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion